ORIC-533
Multiple Myeloma
Phase 1bInferred Active
Key Facts
About ORIC Pharmaceuticals
ORIC Pharmaceuticals is a clinical-stage biotech with a mission to overcome therapeutic resistance in cancer, a primary cause of treatment failure. The company has successfully raised over $900 million, advanced four programs into clinical trials, and is progressing key assets like ORIC-114 and rinzimetostat (ORIC-944) in late-phase 1b/2 studies. Its strategy centers on a proprietary resistance platform to develop combination therapies that extend the efficacy of standard-of-care treatments, positioning it as a potential partner of choice in the oncology landscape.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |